Hi Hannah, there's three things I'd be interested in finding out please!
1. What percentage of the DUK research budget for T1 is allocated towards cure research, and what percentage does that represent of total expenditure?
2. Who are the main corporate donors to Diabetes UK, how much have they donated on a per company basis, and what agreements have been made with those companies in exchange for those donations?
3. Diabetes UK has been instrumental in things like ensuring pen needles are on prescription - what steps is the charity taking to get existing non-invasive BG testing systems such as the Freestyle Libre on prescription?
Hi DeusXM, thanks for your questions, It's so nice to see such an interest in what's happening
🙂
I'm afraid I'll have to delay an answer to Qs 1 & 2 for now, but I didn't want to leave you waiting over the weekend (and a Bank Holiday weekend at that!)
The Research team are kindly having a look at the data to get an answer to Question 1 for me, and I the again, the corporate team are going to give me some informaiton too. They were however, delighted to know what you folk are interested in - so already it looks like these questions can help us to think about the data we share and how we break it down, which is great!
Question 3:
We are in contact with Abbott about the Freestyle Libre and the issue of it being available on prescription. In order for the device to be available, Abbott must apply for National Funding. In order to do this, they need to gather data on the cost effectiveness of the Libre to make the case to governments and insurers for reimbursement (reimbursement would mean the product could be prescribed to individuals through the NHS). They’re still gathering this data which, unfortunately, will take some time. The device therefore cannot currently be considered for inclusion on the prescription database. Abbott’s sole intention at present is to sell the Libre device online direct to patients.
We are continuing to raise this issue with the company about submitting the device for national funding. However, we are not in a position to
insist that Abbott should apply for national funding. Abbott, along with any technology or pharma company are global companies who make marketing decisions based on many factors so, although we can try and influence the company as much as possible, and raise the issues that people raise with us, we can't guarantee that they will act upon these views.
So in short (apologies for the essay!) – We are continuing to put pressure on Abbott to submit the data needed to apply for national funding, as only they can apply for the product to be available on the NHS.
@DeusXM - I hope that helps - I will be back next week with more answers for you
🙂